ceftizoxime (Discontinued)

Brand and Other Names:Cefizox
  • Print

Dosing & Uses

AdultPediatric

Dosage Forms & Strengths

powder for injection

  • 500mg
  • 1g
  • 2g
  • 10g
more...

Gonorrhea (Uncomplicated)

1 g IM (single) dose; 1 g/day maximum

Pelvic Inflammatory Disease

2 g IV q8hr; 6 g/day maximum

Urinary Tract Infection (Uncomplicated)

500 mg IV/IM q12hr

Other Infection Sites

1 g IV/IM q8-12hr

Severe or Refractory Infection

1 g IV/IM q8hr; 2 g q8-12hr IV/IM

Life-Threatening Infection

3-4 g IV q8hr; 9-12 g/day maximum

Renal Impairment

CrCl 50-79 mL/min: 500 mg-1.5 g q8hr

CrCl 5-49 mL/min: 250 mg-1 g q12hr

CrCl <5 mL/min: 250 mg-500 mg qDay or 500 mg-1 g q48hr

Other Indications & Uses

Anaerobic cocci, Bacteroides spp., Citrobacter spp., Clostridium spp., Enterobacter spp., E. coli, H. influenzae, Klebsiella spp., M. morganii, N. gonorrhoeae, P. mirabilis, Providencia rettgeri, Pseudomonas spp., Serratia spp., S. aureus, S. pneumoniae, S. pyogenes

Dosage Forms & Strengths

powder for injection

  • 500mg
  • 1g
  • 2g
  • 10g
more...

Infections

Neonates (off-label): 25-50 mg/kg IV q12hr 

<6 months old (off-label): 100-200 mg/kg/day IV divided q8hr

>6 months old: 150-200 mg/kg/dose IV divided q6-8hr; dosage may be increased to total daily dose of 200 mg/kg

Severe Infection

Neonates (off-label): 25-50 mg/kg IV q12hr 

<6 months old: 100-200 mg/kg/day divided q8hr IV

>6 months old: 200 mg/kg/day IV divided q6-8hr; 12 g/day maximum

Next:

Interactions

Interaction Checker

and ceftizoxime

No Results

     activity indicator 
    No Interactions Found
    Interactions Found

    Contraindicated

      Serious - Use Alternative

        Significant - Monitor Closely

          Minor

            All Interactions Sort By:
             activity indicator 
            Previous
            Next:

            Adverse Effects

            1-10%

            Fever

            Pruritus

            Rash

            Eosinophilia

            Thrombocytosis

            Elevated transaminases, alkaline phosphatase

            Burning at injection site

            <1%

            Anaphylaxis

            Diarrhea

            Nausea/vomiting

            Injection site reactions

            Phlebitis

            Paresthesia

            Numbness

            Increased bilirubin

            Increased BUN

            Increased creatinine

            Anemia

            Leukopenia

            Neutropenia

            Thrombocytopenia

            Vaginitis

            Previous
            Next:

            Warnings

            Contraindications

            Documented hypersensitivity

            Cautions

            Adjust dose in renal impairment; transaminitis, anemia, leukopenia, thrombocytopenia, transient elevations in BUN/creatinine, or GI adverse effects may occur

            Previous
            Next:

            Pregnancy & Lactation

            Pregnancy Category: B

            Lactation: excreted in breast milk; use with caution

            Pregnancy Categories

            A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

            B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

            C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

            D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

            X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

            NA:Information not available.

            more...
            Previous
            Next:

            Pharmacology

            Half-Life: 1.6-1.9 hr, CrCl <10 mL/min: 25 hr

            Peak Plasma Time: IM: 0.5-1 hr

            Protein Bound: 30%

            Distribution: widely into most body tissues & fluids including gallbladder, liver, kidneys, bone, sputum, bile, pleural & synovial fluids; has good CSF penetration; crosses placenta; small amounts enter breast milk

            Vd: 0.35-0.5 L/kg

            Excretion: urine, as unchanged drug

            Mechanism of Action

            Third-generation cephalosporin with broad-spectrum gram-negative activity; lower efficacy against gram-positive organisms; higher efficacy against resistant organisms. Arrests bacterial growth by binding to one or more penicillin-binding proteins

            Previous
            Next:

            Administration

            IV Incompatibilities

            Y-site: filgrastim

            IV Preparation

            Intermittent Injection: add 5, 10, or 20 mL SWI to 500 mg, 1 g, 2 g of ceftizoxime, respectively

            Intermittent/continuous infusion: dilute reconstituted soln w/ 50-100 mL D5W or NS

            IM Injection: add 1.5, 3, or 6 mL SWI to 500 mg, 1 g, or 2 g of ceftizoxime, respectively

            IV Administration

            Intermittent Injection: directly into vein over 3-5 min

            Intermittent/continuous infusion: over 15-30 min

            IM Injection: deeply into large muscle, if administering 2 g, div in 2 doses to 2 different muscle masses

            Previous
            Next:

            Images

            Previous
            Next: